Happy New Year! We have established a new partnership with RareCan which has been founded by our good friend Professor Andy Hall who was instrumental in helping us to establish the National GIST Tissue Bank for GIST research.   You will be aware that GCUK are relentless in our focus to improve treatments and outcomes […]

Today our Patient Director Jayne Bressington participated in the first of a series of RareCan discussions. In this video Jayne and Debbie Binner, Non-executive director of RareCan, discuss their personal experiences of PAWS-GIST and Ewing’s Sarcoma with Professor Andy Hall a Founder and Director of RareCan. Please watch & share this video… By joining RareCan, […]

One of the things patients and their carers tell us they most value about our Patient Meetings is having the opportunity to share experiences with other patients. So when we had to cancel some of this years Patient Meetings due to the pandemic we decided to produce some videos featuring “PAWS-GIST patients talking about their […]

In 2017 GIST Cancer UK approved a research grant application for pathologist Dr Newton Wong to undertake next generation sequencing  (NGS) of wild-type GIST’s to identify therapeutic targets. Earlier this month (July 2020) – Dr Wong’s research paper “Next generation sequencing demonstrates the rarity of short kinase variants specific to quadruple wild type gastrointestinal stromal […]

13th July is GIST Awareness Day! Please help us to reach everyone whose lives are touched by GIST Cancer so they can benefit from the help and support that our GIST Cancer UK community offers. Please click this link. Raising awareness and being aware – here are some more inspiring stories: Jo’s Story   Pippa’s […]

We are very pleased to hear that NICE has approved the Roche drug Entrectinib (Rozlytrek), for use via the Cancer drug fund (CDF) in England by adults and children 12 years and older, who have advanced NTRK (Neurotrophic Tyrosine Receptor Kinase) fusion-positive solid tumours and no satisfactory treatment options. Eligible patients will have access to […]

We are very pleased to announce that NICE has approved the Bayer drug Larotrectinib (Vitrakvi) for use via the Cancer drug fund (CDF) in England for adults and children who have failed other treatment options and whose tumours test positively for the rare NTRK fusion (Neurotrophic Tyrosine Receptor Kinase fusion). Described as an histology agnostic […]

The 17th PAWS-GIST clinic was held at Addenbrookes in Cambridge on 28th & 29th November 2019. Seven patients and their carers joined us for a very helpful clinic as evidenced by the feedback that was received: “I hadn’t realised how much I was holding onto in the weeks before the clinic. Chatting to others helped […]

November continued to be a very exciting month for our PAWS-GIST alliance. From the NCRI awards ceremony in Glasgow we travelled south to Cambridge. Here we met with representatives from Groundwork UK and Tesco who presented us with a cheque for £10,000 which has been awarded to PAWS-GIST as a result of the “Tesco Centenary Grant Award”. This fantastic […]

We are really excited to announce that our PAWS GIST (Paediatric Adolescent Wild-type & Syndromic GIST) alliance has been awarded the National Cancer Research Institute‘s “Collaboration award”. This award recognises our unique European multidisciplinary team of patients, doctors, specialists and researchers who are collaborating to improve treatments and working to find a cure for PAWS-GIST cancer. The nominations were reviewed […]